1. Home
  2. PAR vs FULC Comparison

PAR vs FULC Comparison

Compare PAR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAR Technology Corporation

PAR

PAR Technology Corporation

HOLD

Current Price

$19.09

Market Cap

887.7M

Sector

Miscellaneous

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$8.16

Market Cap

718.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAR
FULC
Founded
1968
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Office Equipment/Supplies/Services
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
887.7M
718.4M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
PAR
FULC
Price
$19.09
$8.16
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
$36.00
$16.38
AVG Volume (30 Days)
1.5M
980.9K
Earning Date
05-29-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$455,547,000.00
N/A
Revenue This Year
$11.10
N/A
Revenue Next Year
$11.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
30.16
N/A
52 Week Low
$15.44
$2.32
52 Week High
$72.15
$15.74

Technical Indicators

Market Signals
Indicator
PAR
FULC
Relative Strength Index (RSI) 39.20 35.70
Support Level N/A $6.33
Resistance Level $22.48 $8.50
Average True Range (ATR) 1.62 0.82
MACD 0.33 -0.20
Stochastic Oscillator 50.57 12.08

Price Performance

Historical Comparison
PAR
FULC

About PAR PAR Technology Corporation

PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Share on Social Networks: